New London facility exceeds global plasmid DNA demand 

Touchlight exterior view London

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK.  

The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing, global supply of plasmid DNA for genetic medicine, and dramatically increases Touchlight’s capacity to meet growing demand for DNA from biopharmaceutical companies. 

Demand for DNA from biopharmaceutical companies is increasing exponentially given its critical role in genetic medicines, including mRNA vaccines and gene therapies, enabling the potential of emerging new drug classes such as gene-editing treatments and novel cancer therapies. Touchlight has contracts to supply many top biopharmaceutical companies, including Pfizer and Lonza. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free